Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 7;29(7):4768-4778.
doi: 10.3390/curroncol29070378.

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

Isaiah MacDonald  1 , Nancy A Nixon  2 , Omar F Khan  2
Affiliations
Review

Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies

Isaiah MacDonald et al. Curr Oncol. .

Abstract

Breast cancer is the most commonly diagnosed malignancy in women, with triple-negative breast cancer (TNBC) accounting for 10-20% of cases. Historically, fewer treatment options have existed for this subtype of breast cancer, with cytotoxic chemotherapy playing a predominant role. This article aims to review the current treatment paradigm for curative-intent TNBC, while also reviewing potential future developments in this landscape. In addition to chemotherapy, recent advances in the understanding of the molecular biology of TNBC have led to promising new studies of targeted and immune checkpoint inhibitor therapies in the curative-intent setting. The appropriate selection of TNBC patient subgroups with a higher likelihood of benefit from treatment is critical to identify the best treatment approach.

Keywords: PARPi; adjuvant; breast cancer; chemotherapy; curative intent; immunotherapy; neoadjuvant; triple negative.

PubMed Disclaimer

Conflict of interest statement

N.A.N. receives research support from AstraZeneca, Pfizer, Merck, Seagen and Novartis. She has received speaker honoraria from AstraZeneca, Pfizer, Merck, Seagen, Roche, Exact science, Eli Lily, Gilead and Novartis. O.F.K. has participated in advisory boards and received speaker honoraria from Pfizer and AstraZeneca.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brenner D.R., Poirier A., Woods R.R., Ellison L.F., Billette J.M., Demers A.A., Zhang S.X., Yao C., Finley C., Fitzgerald N., et al. Projected estimates of cancer in Canada in 2022. CMAJ. 2022;194:E601–E607. doi: 10.1503/cmaj.212097. - DOI - PMC - PubMed
    1. Waks A.G., Winer E.P. Breast cancer treatment: A review. JAMA. 2019;321:288–300. doi: 10.1001/jama.2018.19323. - DOI - PubMed
    1. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., Ollila D.W., Sartor C.I., Graham M.L., Perou C.M. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 2007;13:2329–2334. doi: 10.1158/1078-0432.CCR-06-1109. - DOI - PubMed
    1. Abuhadra N., Stecklein S., Sharma P., Moulder S. Early-stage triple-negative breast cancer: Time to optimize personalized strategies. Oncologist. 2022;27:30–39. doi: 10.1093/oncolo/oyab003. - DOI - PMC - PubMed
    1. Blum J.L., Flynn P.J., Yothers G., Asmar L., Geyer C.E., Jacobs S.A., Robert N.J., Hopkins J.O., O’Shaughnessy J.A., Dang C.T., et al. Anthracyclines in early breast cancer: The ABC trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology) J. Clin. Oncol. 2017;35:2647–2655. doi: 10.1200/JCO.2016.71.4147. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources